abatacept (ABA) — Competitive Intelligence Brief

abatacept (ABA) (abatacept (ABA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4 immunoglobulin fusion protein. Area: Immunology.

marketed CTLA-4 immunoglobulin fusion protein CD80/CD86 Immunology Small molecule

Target snapshot

abatacept (ABA) (abatacept (ABA)) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
abatacept (ABA) TARGET	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
ABT	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
Subcutaneous (SC) abatacept	Subcutaneous (SC) abatacept	Bristol-Myers Squibb	phase 3	T-cell costimulation modulator	CD80/CD86
Abatacept plus	Abatacept plus	Massachusetts General Hospital	phase 3	T-cell costimulation modulator	CD80/CD86
Abatacept (W12-W48)	Abatacept (W12-W48)	University Hospital, Montpellier	phase 3	T-cell costimulation inhibitor	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4 immunoglobulin fusion protein class)

1. Bristol-Myers Squibb · 1 drug in this class